Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1721219

registered interest
date	17/07/2024
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prison Sentences
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to review the cases of those still subject to the "two strikes” sentence imposed under the Powers of Criminal Courts (Sentencing) Act 2000 or the “automatic life" sentence introduced in 2012; and whether there is scope to align their licence conditions with those imposed through the Victims and Prisoners Act 2024 on prisoners serving an indeterminate sentence for public protection.
tabling member printed	Lord Moylan
uin	HL68
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>Section 2 of the Crime (Sentences) Act 1997 (the 1997 Act) introduced a mandatory life sentence for a second serious offence, meaning judges had to impose a life sentence on anyone convicted of a second specified serious offence, unless there were exceptional circumstances.</p><p> </p><p>Although the ‘two-strike’ life sentence and the IPP sentence can be imposed for similar specified offences, unlike the IPP sentence, the ‘two-strike’ life sentence is a life sentence, and offenders will therefore be subject to licence conditions for life if they are released by the Parole Board. The recent changes to the IPP licence, which can be terminated pursuant to section 31A of the 1997 Act, would therefore not align with this life licence.</p><p> </p><p>We will be launching a review of the sentencing framework. The details of this review will be announced in due course.</p> answering member printed Lord Timpson question first answered 29/07/2024 10:03:46 answering member 5364 label Biography information for Lord Timpson
tabling member	4883 label Biography information for Lord Moylan

1668176

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Brain: Tumours
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the All-Party Parliamentary Group on Brain Tumours report Brain Tumours: Pathway to a Cure — breaking down the barriers, published on 28 February, whether they have accepted recommendation six contained in that report that specific funding should be ring-fenced for research into childhood brain tumours; and if so, what is the timescale for implementation.
tabling member printed	Baroness Randerson
uin	HL68
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>It is not usual practice to ring-fence research funds for particular topics or conditions. As with other Government funders of health research, the National Institute for Health and Care Research (NIHR) does not allocate funding for specific disease areas. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p>The Department welcomes the APPG report, recommendations of which continue to be worked through with the Department of Science, Innovation and Technology, and UK Research and Innovation and the Medical Research Council (MRC), and with the NIHR.</p> answering member printed Lord Markham question first answered 13/11/2023 17:49:10 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson

1461041

registered interest
date	10/05/2022
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Legislative Drafting
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what consultation they have undertaken in advance of the development of proposals regarding the review of language used in drafting legislation, following the passage of the Ministerial and other Maternity Allowances Act 2021.
tabling member printed	Lord Hunt of Kings Heath
uin	HL68
answer	answer is ministerial correction date of answer 23/05/2022 answer text <p>Following consideration by the Office of the Parliamentary Counsel, the Government has today issued a written ministerial statement setting out its approach to the use of gendered language in legislative drafting.</p> answering member printed Lord True grouped question UIN HL67 question first answered 23/05/2022 16:42:17 answering member 4200 label Biography information for Lord True
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1313676

registered interest
date	11/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Joint Committee on Vaccination and Immunisation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many civil servants at the Department of Health and Social Care support the work of the Joint Committee on Joint Committee on Vaccination and Immunisation (JCVI); which teams those staff are in; who they are managed by; and how they filter information they provide to the JCVI.
tabling member printed	Lord Mendelsohn
uin	HL68
answer	answer is ministerial correction date of answer 20/05/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is supported by 4.5 full time positions as secretariat to the committee. The secretariat are based in the Immunisation Division in the National Infection Service of Public Health England (PHE) and managed by the Head of Immunisation in PHE.</p><p> </p><p>The secretariat gathers information from a range of sources, including from academic research, PHE and from industry sources. Decisions on information to be shared with the JCVI are made by the secretariat in consultation with consultant epidemiologists, the Head of Immunisation and the Chair of the Committee. Members may also share information with the secretariat or the JCVI. The secretariat are educated to degree level or higher in biological sciences disciplines and are supported by the Head of Immunisation in PHE and a number of consultant epidemiologists and scientists.</p> answering member printed Lord Bethell grouped question UIN HL69 question first answered 20/05/2021 14:18:27 answering member 4708 label Biography information for Lord Bethell
tabling member	4286 label Biography information for Lord Mendelsohn

1168610

registered interest
date	19/12/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: British Nationals Abroad
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking, if any, to ensure continued access for British citizens to health services in the EU after Brexit, including continued access to the benefits of the European Health Insurance Card.
tabling member printed	Baroness Quin
uin	HL68
answer	answer is ministerial correction date of answer 07/01/2020 answer text <p>The agreement we have reached with the European Union is that until 31 December 2020 there will be no changes to reciprocal healthcare access for pensioners, workers, students, tourists and other visitors, the European Health Insurance Card scheme, or planned treatment.</p><p> </p><p>People who have settled in the EU or United Kingdom before 31 December 2020, will continue to have life-long reciprocal healthcare rights provided they remain covered under the terms of the Withdrawal Agreement. This means existing healthcare arrangements will not change for those UK nationals who are resident in the EU and EU citizens in the UK before 31 December 2020, for as long as they are living in that country and covered by the agreement.</p><p> </p><p>We want to continue discussing the future of reciprocal healthcare arrangements with the EU as part of the future relationship discussions.</p> answering member printed Baroness Blackwood of North Oxford question first answered 07/01/2020 12:41:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	518 label Biography information for Baroness Quin

1149775

registered interest
date	14/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bevacizumab
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether there are (1) current applications, or (2) pending requests, for the use of Avastin following Phase 3 clinical trials.
tabling member printed	Lord Willis of Knaresborough
uin	HL68
answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>To extend the indication of Avastin, the Marketing Authorisation Holder (Roche Registration GmbH) would need to submit the results of relevant clinical trials and other information to the European Medicines Agency (EMA) to demonstrate acceptable safety and efficacy and a positive balance of benefit to risk. At present, as Avastin has a European Community Marketing Authorisation, a national submission to the Medicines and Healthcare products Regulatory Agency to extend the indication is not possible.</p><p>There has not been any recent positive opinion from the EMA for a new indication of Avastin to be submitted to the European Commission and the EMA has not published any pending extension of indication applications.</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/10/2019 12:11:29 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4151 label Biography information for Lord Willis of Knaresborough